Former Bos Sci exec fills new clinical development role at Lantheus
Lantheus Medical Imaging has appointed Dana S. Washburn, MD, to the newly created position of vice president, clinical development and medical affairs.
In his new role, the North Billerica, Mass.-based Washburn will be responsible for spearheading the clinical investigation of Lantheus’ pipeline of diagnostic imaging agents and providing ongoing medical and safety support for the company’s existing portfolio, including products such as Definity, Ablavar, Cardiolite and TechneLite. Washburn will be involved in product life cycle management, including clinical trial oversight and the safety and surveillance of marketed products, as well as lead the medical affairs department.
Washburn was most recently vice president, clinical trials and safety, and medical safety officer at Boston Scientific, headquartered in Natick, Mass. Prior to his eight-year tenure at Boston Scientific, Washburn was a cardiologist at the Framingham Heart Center, where he focused on echocardiography and nuclear cardiology.
In his new role, the North Billerica, Mass.-based Washburn will be responsible for spearheading the clinical investigation of Lantheus’ pipeline of diagnostic imaging agents and providing ongoing medical and safety support for the company’s existing portfolio, including products such as Definity, Ablavar, Cardiolite and TechneLite. Washburn will be involved in product life cycle management, including clinical trial oversight and the safety and surveillance of marketed products, as well as lead the medical affairs department.
Washburn was most recently vice president, clinical trials and safety, and medical safety officer at Boston Scientific, headquartered in Natick, Mass. Prior to his eight-year tenure at Boston Scientific, Washburn was a cardiologist at the Framingham Heart Center, where he focused on echocardiography and nuclear cardiology.